Melanocortin Receptor Agonists: Class Overview Monograph

What Are Melanocortin Receptor Agonists?

Melanocortin receptor agonists are a peptide-based drug class that bind and activate one or more of five G-protein-coupled melanocortin receptors (MC1R through MC5R). Unlike peripheral vasodilators or phosphodiesterase-5 inhibitors, these agents work upstream in the central nervous system to modify desire, arousal, and motivation. The only currently approved member of the class for sexual dysfunction is bremelanotide 1.75 mg SC (Vyleesi, AMAG Pharmaceuticals/Palatin Technologies), cleared by the FDA on June 21, 2019 [1].

Receptor Subtypes and Their Roles

The five melanocortin receptor subtypes have distinct tissue distributions and physiological roles:

• MC1R: Expressed on melanocytes and immune cells. Governs skin pigmentation and UV-response. Relevant to the hyperpigmentation side effect seen with chronic MC-agonist use.
• MC2R: Expressed in the adrenal cortex. Binds exclusively ACTH; regulates cortisol synthesis.
• MC3R: Expressed in hypothalamus, limbic system, and brainstem. Modulates energy homeostasis, feeding behavior, and sexual function.
• MC4R: Expressed throughout the CNS, most densely in paraventricular nucleus (PVN). Central to sexual desire signaling, erectile function, and satiety. Mutations in MC4R account for up to 6% of severe early-onset obesity cases [2].
• MC5R: Expressed in exocrine glands and peripheral tissues. Role in sexual function is less characterized.

Bremelanotide is a non-selective agonist with affinity at MC1R, MC3R, MC4R, and MC5R, with greatest clinical relevance at MC3R and MC4R in the hypothalamus.

Endogenous Melanocortin Ligands

The endogenous ligands for these receptors are all derived from the proopiomelanocortin (POMC) precursor protein, cleaved post-translationally in the pituitary and hypothalamus. The primary endogenous agonists include:

• Alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid peptide that activates MC1R, MC3R, MC4R, and MC5R
• Beta-MSH and gamma-MSH, with overlapping but distinct receptor selectivity
• ACTH, which preferentially activates MC2R

Bremelanotide is a cyclic heptapeptide analog of alpha-MSH, engineered for metabolic stability and improved CNS penetrance compared to the native peptide.

Pharmacology and Mechanism of Action

Central Sexual Desire Pathway

Sexual desire originates in part from tonic activity of POMC neurons in the arcuate nucleus, which project to the PVN and limbic areas. MC4R activation in the PVN triggers downstream release of oxytocin, and animal models show direct effects on dopaminergic reward circuits [3]. This central mechanism distinguishes melanocortin agonists from all peripherally acting sexual dysfunction drugs.

Bremelanotide administered subcutaneously crosses the blood-brain barrier within 30 to 45 minutes, produces peak CNS exposure near the time of anticipated sexual activity, and returns to sub-pharmacological concentrations within 12 hours. The mechanism does not depend on genital blood flow, hormone levels, or physical stimulation alone, which explains why it can benefit women whose HSDD has a central rather than hormonal etiology.

Pharmacokinetics of Bremelanotide

| Parameter | Value | |---|---| | Route | Subcutaneous (abdomen or thigh) | | Tmax | 1 hour | | Half-life (t1/2) | Approximately 2.7 hours | | Protein binding | Approximately 21% | | Metabolism | Proteolytic (not CYP450-mediated) | | Elimination | Primarily renal (64%) and fecal (22%) | | Bioavailability (SC) | ~100% |

Because bremelanotide is not a CYP substrate, classic drug-drug interactions via hepatic enzyme induction or inhibition do not apply. However, due to transient slowing of gastric motility and gastric emptying post-injection, absorption of orally co-administered drugs may be delayed by 1 to 2 hours [1].

Receptor Selectivity of Key Agents

Bremelanotide has lower MC4R selectivity compared to investigational agents such as setmelanotide (which is MC4R-sparing and MC4R-selective at different nodes) and PL-8177. This non-selectivity explains both its efficacy for desire (MC3R/MC4R) and its side effects, including nausea (central MC receptors) and potential pigmentation changes (MC1R on melanocytes).

Approved Agents in the Class

Bremelanotide (Vyleesi)

Bremelanotide is the prototype clinical agent and the only FDA-approved melanocortin agonist for sexual dysfunction. It originated from PT-141, a metabolite of the tanning peptide Melanotan II, and was reformulated into a subcutaneous autoinjector for commercial use.

Approved indication: Acquired, generalized HSDD in premenopausal women, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria [1].

Dose: 1.75 mg SC approximately 45 minutes before sexual activity. No more than once in 24 hours.

Key trials: The RECONNECT program consisted of two Phase 3 randomized, double-blind, placebo-controlled trials (Study 301 and Study 302) enrolling a combined 1,267 premenopausal women with generalized acquired HSDD [4]. At the end of the 24-week treatment period:

• Women receiving bremelanotide had a statistically significant increase in the Female Sexual Function Index (FSFI) desire domain score vs. Placebo (P<0.001 in both studies) [4].
• The proportion of women reporting a clinically meaningful improvement in desire (defined as a 0.6-point increase on the eDiary desire score) was significantly higher in the bremelanotide group.
• Distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) improved significantly vs. Placebo [4].

The FDA's prescribing information notes: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance." [1]

Setmelanotide (Imcivree)

Setmelanotide is an MC4R-selective agonist FDA-approved in November 2020, but for a completely different indication: chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome [5]. Its high MC4R selectivity minimizes MC1R-mediated pigmentation effects less effectively than hoped, and hyperpigmentation remains a labeled risk [5]. Prescribers should not confuse this agent with bremelanotide; they share a drug class but have no overlapping approved indications.

Off-Label and Compounded Agents

Compounded PT-141

PT-141 refers to the peptide bremelanotide prior to its commercial reformulation. Compounding pharmacies prepare PT-141 as a subcutaneous injection or intranasal spray, typically at doses ranging from 0.5 mg to 2 mg per use. It is prescribed off-label for:

• HSDD in premenopausal and postmenopausal women
• Low libido or arousal dysfunction in men
• Erectile dysfunction refractory to PDE5 inhibitors, particularly in men with psychogenic or desire-based components

The pharmacological activity of compounded PT-141 is expected to match bremelanotide given identical amino acid sequences, but compounded products are not FDA-reviewed for purity, potency, or sterility on a batch basis. Prescribers should use FDA-registered 503B outsourcing facilities when compounded PT-141 is selected.

Clinical decision framework for compounded PT-141 vs. Bremelanotide (Vyleesi):

| Clinical scenario | Preferred agent | |---|---| | Premenopausal woman with acquired generalized HSDD, insurance coverage possible | Bremelanotide (Vyleesi) 1.75 mg SC | | Postmenopausal woman with HSDD | Compounded PT-141 (off-label) | | Man with low libido or psychogenic ED | Compounded PT-141 (off-label) | | Patient preferring intranasal route | Compounded PT-141 intranasal (off-label) | | Patient with uncontrolled hypertension | Neither; defer until blood pressure controlled |

Prescribing Considerations

Indications and Patient Selection

Bremelanotide carries a narrow FDA-approved label. Premenopausal women with acquired, generalized HSDD represent the only labeled population. Before prescribing, the clinician should confirm:

1. The desire disorder is not better explained by a relationship problem, untreated depression, a medication side effect (SSRIs, hormonal contraceptives, antipsychotics), or an underlying endocrine disorder.
2. Thyroid function, prolactin, and total testosterone levels are within normal limits, or any abnormalities have been addressed.
3. The patient understands the PRN dosing model and realistic expectations.

The North American Menopause Society (NAMS) 2022 position statement on sexual health states that HSDD evaluation should incorporate validated tools such as the FSFI and FSDS-DAO before initiating pharmacotherapy [6].

Dosing and Administration

• Standard dose: 1.75 mg SC via autoinjector to abdomen or thigh, 45 minutes before sexual activity.
• No dose titration is required or FDA-approved for bremelanotide.
• Frequency cap: Once per 24-hour period. No daily use.
• Patients should be trained on autoinjector technique at the first visit.
• The injection site should be rotated to reduce local reaction risk.

For compounded PT-141:

• Subcutaneous doses typically range from 1 mg to 2 mg.
• Intranasal doses typically range from 0.5 mg to 1 mg, though intranasal bioavailability is lower and more variable.
• No standardized dosing guidelines exist for the intranasal route.

Contraindications

Bremelanotide is contraindicated in:

• Patients with known cardiovascular disease (uncontrolled hypertension, history of cardiac events). The drug produces a transient mean increase in systolic blood pressure of 2 mmHg and diastolic blood pressure of 1 mmHg, peaking at approximately 4 hours post-dose, with resolution by 12 hours [1]. Patients with borderline or elevated baseline blood pressure require careful risk-benefit evaluation.
• Patients taking naltrexone, because naltrexone blunts the endogenous opioid-melanocortin interaction and may reduce efficacy. This applies to both oral naltrexone and injectable naltrexone (Vivitrol).

Safety Profile and Adverse Effects

| Adverse effect | Incidence in RECONNECT trials | Notes | |---|---|---| | Nausea | 40% | Most common; typically mild to moderate, resolves within 1 hour | | Flushing | 20% | Transient; related to MC receptor vasodilation | | Injection site reactions | 13% | Bruising, pain, redness | | Headache | 11% | Usually mild | | Transient hypertension | 13% | Monitor in patients with cardiovascular risk | | Hyperpigmentation | Reported with chronic use | MC1R-mediated; most common on face, breasts, gingiva |

Approximately 40% of women in the RECONNECT trials discontinued due to adverse effects, primarily nausea [4]. Pre-treating with ondansetron 4 mg orally 30 minutes before the bremelanotide injection may reduce nausea severity, though this is not an FDA-labeled recommendation and represents clinical practice.

Monitoring Parameters

No routine laboratory monitoring is required for bremelanotide used at the approved dose and frequency. For patients using compounded PT-141 more frequently or at higher doses:

• Blood pressure at baseline and periodically
• Skin examination for hyperpigmentation, particularly with use beyond 6 months
• FSFI and FSDS-DAO scores at 4 to 8 weeks to assess clinical response

A trial period of 8 weeks (approximately 8 uses at weekly frequency) is a reasonable threshold to evaluate response before concluding the agent is ineffective.

Special Populations

Postmenopausal Women

Bremelanotide has not been studied in postmenopausal women, and its FDA label explicitly excludes this population. Despite this, compounded PT-141 is used clinically in postmenopausal women with HSDD, often alongside systemic or vaginal estrogen and testosterone therapy. The central MC4R mechanism is not estrogen-dependent, which provides rationale for potential benefit independent of hormonal status, but controlled trial data in this population are absent.

Men

PT-141 was originally investigated for erectile dysfunction in men. A Phase 2 trial published in the Journal of Sexual Medicine demonstrated that intranasal PT-141 at doses of 7.5 mg and 10 mg produced significantly greater erectile response than placebo in men with mild to moderate ED (P<0.01) [7]. Men with psychogenic ED or low sexual desire may represent the best candidates, as the central desire pathway is relevant regardless of sex. No commercial product is FDA-approved for men in this class.

Hepatic and Renal Impairment

No dose adjustment is required for mild to moderate hepatic impairment. Bremelanotide has not been studied in severe hepatic impairment. For renal impairment, no dose adjustment is needed for mild to moderate impairment; pharmacokinetic data in severe renal impairment (eGFR <30 mL/min/1.73 m²) are limited and the prescribing information advises caution [1].

Pregnancy and Lactation

Bremelanotide is contraindicated in pregnancy. Animal studies showed embryo-fetal toxicity at exposures below the clinical dose. Women of reproductive potential should use effective contraception during treatment. Excretion into human breast milk has not been studied; avoidance during breastfeeding is recommended [1].

Investigational Agents and Future Directions

MC4R-Selective Peptides

Several MC4R-selective peptides are in preclinical and early clinical development aimed at sexual dysfunction with a cleaner side-effect profile than non-selective agents. Greater MC4R selectivity could reduce nausea (which may involve MC1R/MC3R peripheral activity) while maintaining central desire effects.

Small-Molecule MC4R Agonists

Peptide drugs require injection, which limits long-term adherence for some patients. Oral small-molecule MC4R agonists are being explored; the challenge is achieving sufficient CNS penetration without off-target peripheral MC receptor activation. No small-molecule MCR agonist is currently in Phase 3 development for sexual dysfunction as of the date of this publication.

Combination Approaches

Investigators have studied whether combining low-dose melanocortin agonism with dopaminergic agents (such as bupropion) or oxytocin agonists could produce additive desire enhancement at lower individual doses. Data remain preliminary.

Regulatory and Prescribing Context

Bremelanotide (Vyleesi) is a Schedule-uncontrolled prescription drug, available by prescription only. It is not a controlled substance. Prior authorization is common for commercial insurance; the manufacturer offered a savings program historically. Telehealth prescribing of bremelanotide is legally permissible under standard prescribing authority without the DEA special registration required for controlled substances.

Compounded PT-141 is not FDA-approved and does not have a standard of care designation. Prescribers using it off-label should document the clinical rationale, informed consent regarding off-label and compounded status, the absence of a commercially available FDA-approved alternative appropriate for the patient (where applicable), and the selection of a reputable compounding pharmacy.

The FDA issued a 2023 guidance reminder that bulk drug substances used in compounding must appear on the 503A or 503B nominated substance lists or meet other statutory criteria; PT-141 (bremelanotide) as a bulk substance occupies a regulatory gray zone that prescribers should monitor [8].

Comparison to Other Sexual Dysfunction Drug Classes

| Drug class | Prototype | Mechanism | Primary effect | Route | |---|---|---|---|---| | Melanocortin agonists | Bremelanotide | Central MC3R/MC4R agonism | Increases desire | SC injection | | PDE5 inhibitors | Sildenafil | Blocks PDE5, increases cGMP | Increases genital blood flow | Oral | | SNRI/dopamine modulator | Flibanserin (Addyi) | 5-HT1A agonist/5-HT2A antagonist | Reduces serotonin inhibition of desire | Oral daily | | Testosterone (off-label) | Testosterone cypionate | Androgen receptor agonism | Increases desire, energy | IM or transdermal | | Ospemifene | Osphena | SERM | Reduces vaginal atrophy | Oral |

Flibanserin (Addyi) requires daily oral dosing and carries a Risk Evaluation and Mitigation Strategy (REMS) requiring abstinence from alcohol, whereas bremelanotide is PRN and has no REMS requirement [9]. For patients who cannot commit to daily dosing or who prefer an on-demand agent, bremelanotide has a practical advantage.